Evidence method
Level · gp.fundamentals.debt_to_revenue
0.00% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ABUS · Jun 30, 2026
Arbutus Biopharma Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001447028-26-000045General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-593.49% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-90.56% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-588.17% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
285.80% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
157.30% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History11 statesHistory building
Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/7 normalizedLevel 3Jun 30, 20256/7 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20257/7 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- -4.53%
- Current
- -593.49%
- Delta
- -588.96%
- Previous
- 10054.54%
- Current
- -90.56%
- Delta
- -10145.09%
- Previous
- 94.30%
- Current
- -588.17%
- Delta
- -682.46%
- Previous
- 2.30%
- Current
- 285.80%
- Delta
- 283.50%
- Previous
- 0.76%
- Current
- 157.30%
- Delta
- 156.54%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Pharmaceutical Preparations peers →Transitioned To · ABUS Fundamental State →Transitioned To · ABUS CASH_GENERATION_DECREASED →Transitioned To · ABUS GROWTH_DECREASED →Transitioned To · ABUS PROFITABILITY_DECREASED →Transitioned To · ABUS R_AND_D_INTENSITY_INCREASED →Transitioned To · ABUS SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.